Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine

Clinical and Translational Oncology

Volumn 16, Issue 7, 2014, Pages 637-643

  Juan, O ^a   Vidal, J ^b   Gisbert, R ^b   Munoz J ^c   Macia S ^d   Gomez Codina J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d HOSPITAL GENERAL DE ELDA   (Spain)

Author keywords

Circulating tumor cells; Lung cancer; Non small cell lung cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DOCETAXEL; GEMCITABINE; TAXOID; TUMOR MARKER;

ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905680559     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1128-8     Document Type: Article

References (30)

1. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, EUROCARE Working group, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8:773-83. (Pubitemid 47321600)
2. Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2007;57:348-58. (Pubitemid 47285418)
3. Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, et al. Treatment of advanced non-small cell lung cancer patients with ECOG performance status 2: results of an European experts panel. Ann Oncol. 2004;15:419-26. (Pubitemid 38444544)
4. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000;27:145-57. (Pubitemid 30105654)
5. Lilenbaum RC, Herndon JE 2nd, List MA, Desch C, Watson DM, Miller AA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the cancer and leukemia group B. J Clin Oncol. 2005;23:190-6. (Pubitemid 41702638)
6. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23:2937-45. (Pubitemid 46224112)
7. Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morère JF, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol. 2005;16:602-10. (Pubitemid 40613327)
8. Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Greek Cooperative Group for Lung Cancer, et al. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer. 2001;34:S47-51.
9. Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, et al. Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study. Lung Cancer. 2009;63:77-82.
10. Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008;59:57-63.
11. Pallis A, Polyzos A, Boukovinas I, Agelidou A, Lamvakas L, Tsiafaki X, et al. Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience. J Thorac Oncol. 2008;3:505-10. (Pubitemid 351630278)
12. O'Flaherty JD, Gray S, Richard D, Fennell D, O'Leary JJ, Blackhall FH, et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer. 2012;76:19-25.
13. Allard WJ. Tumor cell circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant disease. Clin Cancer Res. 2004;10:6897-904. (Pubitemid 39383039)
14. Maestro LM, Sastre J, Rafael SB, Veganzones SB, Vidaurreta M, Martín M, et al. Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res. 2009;29:4839-43.
15. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421.
16. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213-21.
17. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-91. (Pubitemid 39095313)
18. Budd G, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging: predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403-9. (Pubitemid 44799711)
19. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognosis significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29:1556-63.
20. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res. 2007;13:920-8. (Pubitemid 46340368)
21. Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R, et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 2002;49:150-8. (Pubitemid 37087227)
22. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 2000;156:57-63. (Pubitemid 30644439)
23. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumor cells in cancer patients by microchip technology. Nature. 2007;53:1235-9.
24. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-9.
25. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, et al. Detection of EpCAM and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol. 2011;2011:252361.
26. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat. 2011;130:449-55.
27. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, et al. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer. 2011;129:417-23.
28. Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol. 2008;19:891-7. (Pubitemid 351627303)
29. Naito T, Tanaka F, Ono A, Yoneda K, Takahashi T, Murakami H, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol. 2012;7:512-9.
30. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366-77.